Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1Gynecologic 1

Conditions

Vomiting 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Aprepitant × 1 year × Clear all
NCT06007586 2025-12-04

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

Sichuan Cancer Hospital and Research Institute

Phase 3 Completed
143 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Vomiting, Endometrial Neoplasms

NCT03808805 2025-12-03

APHYPAP

University Hospital, Brest

Phase 3 Completed
63 enrolled
Myeloid

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡